Eli Lilly and Company

Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52 (2021) Behrens F, Leage SL, Sapin C, El Baou C, De La Torre I, Meszaros G, Schett G, et al. Journal article PREFERENCES FOR TREATMENTS TO PREVENT RHEUMATOID ARTHRITIS: DISCRETE CHOICE SURVEY OF GENERAL POPULATIONS IN UNITED KINGDOM, GERMANY, AND ROMANIA (2021) Simons G, Veldwijk J, Di Santostefano R, Englbrecht M, Radawski C, Valor L, Raza K, Falahee M Journal article Treatment preferences for preventive interventions for rheumatoid arthritis: Protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project (2021) Falahee M, Simons G, Disantostefano RL, Valor Méndez L, Radawski C, Englbrecht M, Schölin Bywall K, et al. Journal article, Original article High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE (2021) Harbeck N, Johnston S, Fasching P, Martin M, Toi M, Rastogi P, Song C, et al. Conference contribution Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24 (2020) Smolen J, Behrens F, Liu-Leage S, Sapin C, De La Torre I, Meszaros G, Schett G, et al. Conference contribution Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks (2020) Schett G, Van Den Bosch F, Baraliakos X, Sandoval D, Geneus V, Bolce R, Liu-Leage S, et al. Conference contribution Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis (2020) Guermazi A, Roemer F, Kompel A, Diaz L, Crema M, Brown M, Hickman A, et al. Conference contribution Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety (2020) Markman JD, Bolash RB, Mcalindon TE, Kivitz AJ, Pombo-Suarez M, Ohtori S, Roemer F, et al. Journal article TARGET OUTCOMES IN PSA: SIMULTANEOUS ACHIEVEMENT OF ACR50-PASI100 AND BEYOND: INSIGHTS FROM SPIRIT-H2H AT WEEK 24 (2020) Smolen JS, Behrens F, Leage SL, Sapin C, De La Torre I, Meszaros G, Schett G, et al. Conference contribution A Phase 2 Study of Galunisertib (TGF-beta 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (2019) Kelley RK, Gane E, Assenat E, Galle PR, Merle P, Hourmand IO, Cleverly A, et al. Journal article